| HLX02 |
Healthy Male Subjects
|
Phase I
|
A Study of Safety and Tolerability of HLX02 with Different Dose and a Phase I Study Comparing HLX02 and Herceptin®(U.S. and German)
|
| HLX02 |
BC
|
Phase III
|
A Phase III Study Comparing the Safety and Efficacy of HLX02 and Herceptin®(U.S. and German) in Breast Cancer
|
| HLX01 |
CD20-Positive B-cell Lymphomas
|
Phase Ia
|
A Phase Ia Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients with CD20-positive B-cell Lymphomas
|
| HLX01 |
CD20-positive B-cell Lymphomas
|
Phase I
|
A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 and Rituximab
|
| HLX01 |
DLBCL
|
Phase III
|
Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 in Combination with CHOP and Rituximab in Combination with CHOP
|
